
The approval was based on phase 3 data showing survival rates of 83.3% after three years

The oligonucleotide telomerase inhibitor is administered as an intravenous infusion every four weeks

Fusion protein, bintrafusp alfa – the centrepiece of the 2019 GSK/Merck partnership – has failed to meet its latest trial endpoint and the trial is to be discontinued

Submission is based on top-line efficacy and safety data from the phase 3 ENSEMBLE trial

Final analysis demonstrates a 35% reduction in the risk of death in mHSPC patients

Vaccine was 57% effective against South African strain

Chief scientific officer Paul Stoffels said J&J is aiming for one billion doses in 2021

ENSEMBLE study will enrol 60,000 people worldwide

Agreement includes manufacturing and delivery of 100 million doses

Experimental vaccine begins first-in-human trial this month

Potential treatment for patient group with no FDA-approved drugs

Shares drop by two-thirds as questions raised on imetelstat’s potential